AAAAAA
Results:
1-13
|
Results: 13
Authors:
Littlewood, TJ
Bajetta, E
Nortier, JWR
Vercammen, E
Rapoport, B
Citation: Tj. Littlewood et al., Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized,double-blind, placebo-controlled trial, J CL ONCOL, 19(11), 2001, pp. 2865-2874
Authors:
Littlewood, TJ
Citation: Tj. Littlewood, Erythropoietin for the treatment of anemia associated with hematological malignancy, HEMATOL ONC, 19(1), 2001, pp. 19-30
Authors:
Littlewood, TJ
Citation: Tj. Littlewood, The impact of hemoglobin levels on treatment outcomes in patients with cancer, SEMIN ONCOL, 28(2), 2001, pp. 49-53
Authors:
Best, D
Pasquet, S
Littlewood, TJ
Brunskill, SJ
Pallister, CJ
Watson, SP
Citation: D. Best et al., Platelet activation via the collagen receptor GPVI is not altered in platelets from chronic myeloid leukaemia patients despite the presence of the constitutively phosphorylated adapter protein CrkL, BR J HAEM, 112(3), 2001, pp. 609-615
Authors:
Jackson, G
Taylor, P
Smith, GM
Marcus, R
Smith, A
Chu, P
Littlewood, TJ
Duncombe, A
Hutchinson, M
Mehta, AB
Johnson, SA
Carey, P
Mackie, MJ
Ganly, PS
Turner, GE
Deane, M
Schey, S
Brookes, J
Tollerfield, SM
Wilson, MP
Citation: G. Jackson et al., A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation, BR J HAEM, 112(1), 2001, pp. 127-137
Authors:
Gooptu, C
Littlewood, TJ
Frith, P
Lyon, CC
Carmichael, AJ
Oliwiecki, S
MacWhannell, A
Amagai, M
Hashimoto, T
Dean, D
Allen, J
Wojnarowska, F
Citation: C. Gooptu et al., Paraneoplastic pemphigus: an association with fludarabine?, BR J DERM, 144(6), 2001, pp. 1255-1261
Authors:
Sternberg, AJ
Lee, G
Croxton, T
Mundy, N
Morris, P
Littlewood, TJ
Murphy, MF
Citation: Aj. Sternberg et al., Severe haemolysis after an ABO unmatched kidney transplant - a nonsecretortransplanted from a donor with high anti-A titre, TRANSFUS M, 10(1), 2000, pp. 87-89
Authors:
Atoyebi, W
Mundy, N
Croxton, T
Littlewood, TJ
Murphy, MF
Citation: W. Atoyebi et al., Is it necessary to administer anti-D to prevent RhD immunization after thetransfusion of RhD-positive platelet concentrates?, BR J HAEM, 111(3), 2000, pp. 980-983
Authors:
Parameswaran, R
Giles, C
Boots, M
Littlewood, TJ
Mills, MJ
Kelsey, SM
Samson, D
Citation: R. Parameswaran et al., CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma, BR J HAEM, 109(3), 2000, pp. 571-575
Authors:
Propper, DJ
Levitt, NC
O'Byrne, K
Braybrooke, JP
Talbot, DC
Ganesan, TS
Thompson, CH
Rajagopalan, B
Littlewood, TJ
Dixon, RM
Harris, AL
Citation: Dj. Propper et al., Phase II study of the oxygen saturation curve left shifting agent BW12C incombination with the hypoxia activated drug mitomycin C in advanced colorectal cancer, BR J CANC, 82(11), 2000, pp. 1776-1782
Authors:
Boultwood, J
Peniket, A
Watkins, F
Shepherd, P
McGale, P
Richards, S
Fidler, C
Littlewood, TJ
Wainscoat, JS
Citation: J. Boultwood et al., Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase, BLOOD, 96(1), 2000, pp. 358-361
Authors:
Boultwood, J
Fidler, C
Shepherd, P
Watkins, F
Snowball, J
Haynes, S
Kusec, R
Gaiger, A
Littlewood, TJ
Peniket, AJ
Wainscoat, JS
Citation: J. Boultwood et al., Telomere length shortening is associated with disease evolution in chronicmyelogenous leukemia, AM J HEMAT, 61(1), 1999, pp. 5-9
Authors:
Schuh, A
Dandridge, J
Haydon, P
Littlewood, TJ
Citation: A. Schuh et al., Encephalopathy complicating high-dose melphalan, BONE MAR TR, 24(10), 1999, pp. 1141-1143
Risultati:
1-13
|